Trials / Terminated
TerminatedNCT05106335
A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
A Randomized, Open-Label, Controlled, Multi-Center Phase III Clinical Study of Camrelizumab Combined With Famitinib Malate Versus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer Who Progressed on Prior Immune Checkpoint Inhibitor Treatment and Platinum-Based Chemotherapy
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, open-label, international, multi-center, phase III trial to evaluate the efficacy, and safety of camrelizumab combined with famitinib malate versus docetaxel as subsequent therapy in Advanced NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | camrelizumab + famitinib | camrelizumab for intravenous injection; famitinib malate capsules for oral administration |
| DRUG | famitinib | famitinib malate capsules for oral administration |
| DRUG | docetaxel | docetaxel for intravenous injection |
Timeline
- Start date
- 2022-01-06
- Primary completion
- 2022-05-11
- Completion
- 2022-05-11
- First posted
- 2021-11-03
- Last updated
- 2023-08-16
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05106335. Inclusion in this directory is not an endorsement.